The Lancet. Oncology 2025 Mar
Destroy or delay: hormonal therapy in oligometastatic prostate cancer.
Related Questions
This question is part of our collaboration with ASTRO 2025 to highlight impactful trial data from this year's meeting. This question is inspired by th...
New answer by Radiation Oncologist at David Geffen School of Medicine at UCLA (September 28, 2025)
The LUNAR approach was designed for men who did not want to have hormone therapy. It is true that hormone therapy, either via ADT, ARPI, or both, could be added to MDT as well...